You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. SONOMA PHARMACEUTICALS INC.

Sonoma Pharmaceuticals Inc. XNAS: SNOA

Sonoma Pharmaceuticals Inc. Live Share Price Today, Share Analysis and Chart

Download real time

3.48 -0.14 (-3.87%)

41.32% Fall from 52W High

117.5K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Sonoma Pharmaceuticals Inc. Key Metrics

Select

Market Capitalization

Low in industry
5.6

PE TTM

Negative PE TTM
-1.5

PEG TTM

Negative PEG TTM
-0.1

Price to Book

Below industry Median
1.2

Institutional holding current Qtr %

Low in industry
1.3

Revenue Growth Qtr YoY %

Below industry Median
13.6

Operating Revenue growth TTM %

Below industry Median
13.5

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-7.2

Net Profit TTM Growth %

Below industry Median
26.2

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-28.9

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-31.9

Piotroski Score

Below industry Median
3

Rel Perf vs Sector quarter%

23.7

ROE Annual %

Negative ROE Annual %
-68.5

RoA Annual %

Negative RoA Annual %
-31.2
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
25.5 / 100
Momentum Score
Technically Moderately Bullish
66.3 / 100
Analyst Price Target
17
1Yr Price target upside is 389%
1 analysts

21

S

6

W

1

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Sonoma Pharmaceuticals Inc. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Mar '24Mar '25Mar '2610152012.517.5Actual RevenueAvg. Estimate
Miss

Sonoma Pharmaceuticals Inc.'s Revenue was lower than average estimate 1 time in past 1 year

EPS forecast

Current EPS
-10.6
Avg. Estimate
-0.7
Low Estimate
-0.7
High Estimate
-0.7
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 93.7% in FY25

Consensus Recommendation

1 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Strong Buy

The consensus recommendation from 1 analyst for Sonoma Pharmaceuticals Inc. is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Sonoma Pharmaceuticals Inc. Stock Analysis

Sonoma Pharmaceuticals Inc. stock analysis with key metrics, changes, and trends.

Sonoma Pharmaceuticals Inc. MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$12.74 M4.05%negative

Annual Revenue fell 4.05%, in the last year to $12.74 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$4.84 M6.13%positive

Annual Net Profit rose 6.13% in the last year to $4.84 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio-1.5-negative

Price to Earning Ratio is -1.5, which is negative.

Stock Price$3.482576.92%positive

Stock Price rose 2,576.92% and outperformed its sector by 2,567.85% in the past year.

Quarterly Revenue$3.56 M13.58%positive

Quarterly Revenue rose 13.58% YoY to $3.56 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$0.93 M7.16%negative

Quarterly Net profit fell 7.16% YoY to $0.93 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Debt to Equity Ratio0.1-positive

Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-68.51 %-68.51%negative

Return on Equity(ROE) for the last financial year was -68.51%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.61 %-0.13%negative

Mutual Fund Holding decreased by 0.13% in the last quarter to 0.61.

Promoter Share Holding27.10 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 27.1%.

Institutional Holding1.25 %-2.33%negative

Institutional Holding decreased by 2.33% in the last quarter to 1.25.

VIEW LESS


Loading data..

Sonoma Pharmaceuticals Inc. - Company Profile

What does Sonoma Pharmaceuticals Inc. do?

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals Inc. Management structure

All Gross Remunerations are in USD
Ms. Amy Trombly
Director, President and Chief Executive Officer
726.54 K
2024
Gross Remuneration
Year
Mr. Bruce Thornton
Executive Vice President, Chief Operating Officer and Corporate Secretary
658.67 K
2024
Gross Remuneration
Year
Mr. Jerry Dvonch
Interim Chief Financial Officer
307.46 K
2024
Gross Remuneration
Year
Mr. John Dal Poggetto
Controller
-
2024
Gross Remuneration
Year
Mr. Chad White
Chief Financial Officer
-
2024
Gross Remuneration
Year
Mr. Jerome J. Dvonch
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Sonoma Pharmaceuticals Inc. Board of directors

All Gross Remunerations are in USD
Mr. Jerry McLaughlin
Lead Independent Director
65 K
2024
Gross Remuneration
Year
Dr. Jay Edward Birnbaum
Independent Director
55 K
2024
Gross Remuneration
Year
Mr. Philippe Weigerstorfer
Independent Director
47.5 K
2024
Gross Remuneration
Year
Ms. Amy Trombly
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Sonoma Pharmaceuticals Inc. FAQ

How is Sonoma Pharmaceuticals Inc. today?
Sonoma Pharmaceuticals Inc. today is trading in the red, and is down by -3.87% at 3.48.
Sonoma Pharmaceuticals Inc. is currently trading down -3.87% on an intraday basis. In the past week the stock fell -1.42%. stock has been up 32.32% in the past quarter and rose 2576.92% in the past year. You can view this in the overview section.